NCT02998775View on ClinicalTrials.gov

Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 2, 2016

Primary Completion Date

July 8, 2017

Study Completion Date

July 8, 2017

Conditions

Hepatic Impairment; Renal Impairment

Interventions

DRUG

Plasma Sampling

No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.

Trial Locations (3)

Unknown

Orlando Clinical Research Center, Inc., Orlando

DaVita Clinical Research, Minneapolis

New Orleans Center for Clinical Research, Knoxville

All Listed Sponsors

lead

Eisai Inc.

INDUSTRY

NCT02998775 - Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding | Biotech Hunter | Biotech Hunter